Propofol differentially inhibits the release of glutamate, γ-aminobutyric acid and glycine in the spinal dorsal horn of rats

Jing Yang 1, Wei Wang 2, Zheng Yong 3, Weidong Mi 1*, Hong Zhang 1

1 Department of Anesthesiology, Chinese People Liberation Army (PLA) General Hospital, Beijing 100853, China
2 Department of Orthopedics, Chinese People Liberation Army (PLA) General Hospital, Beijing 100853, China
3 Department of Pharmacology, Institution of Pharmacology and Toxicology, 100039, China

ABSTRACT

Objective(s): Propofol (2, 6-diisopropylphenol) is an intravenous anesthetic that is commonly used for the general anesthesia. It is well known that the spinal cord is one of the working targets of general anesthetics including propofol. However, there is a lack of investigation of the effects of propofol on spinal dorsal horn which is important for the sensory transmission of nociceptive signals. The objective of this study was to investigate the effects of increasing dosage of propofol on the release of glutamate (Glu), γ-aminobutyric acid (GABA) and glycine (Gly) in the spinal dorsal horn.

Materials and Methods: The efflux of Glu, GABA or Gly in the spinal dorsal horn of rats was detected using transverse spinal microdialysis under an awake condition and various depths of propofol anesthesia. The infusion rates of propofol were, in order, 400 µg/(kg·min), 600 µg/(kg·min) and 800 µg/(kg·min), with a 20 min infusion period being maintained at each infusion rate.

Results: Propofol decreased the glutamate efflux within spinal dorsal horn in a dose-dependent manner, and the maximum decrease was 56.8 ± 6.0% at high-dose propofol infusion producing immobility. The inhibitory GABA and Gly efflux was also decreased about 15–20% at low-dose propofol infusion only producing sedation, but did not continue to drop with higher doses of propofol.

Conclusion: Propofol decreased both excitatory and inhibitory amino acids efflux in spinal dorsal horn, and the preferential suppression of the excitatory amino acid might be associated with the analgesic effect of propofol.

Please cite this article as:
Yang J, Wang W, Yong Zh, Mi W, Zhang H. Propofol differentially inhibits the release of glutamate, γ-aminobutyric acid and glycine in the spinal dorsal horn of rats. Iran J Basic Med Sci 2015; 18:822-826.

Introduction

Propofol (2, 6-diisopropylphenol) is an IV anesthetic that is widely used for the induction and maintenance of general anesthesia. It is well known that the spinal cord is one of the working targets of general anesthetics including propofol. In the spinal cord, the anesthetics might suppress the sensory transmission of nociceptive signals within the dorsal horn and the neuronal activity in the ventral horn (1). While neurons in the spinal ventral horn seem to be more susceptible to propofol (2), the dorsal horn neurons still serve as a potent target for anesthetics to suppress the processing of sensory afferent information (3).

It was shown that general anesthetics produced a profound suppression of the activity of dorsal horn neurons induced by peripheral noxious (4). Previous study reported that propofol, in anesthetic doses, directly depressed neuronal activity in the lumbar dorsal horn with minimal indirect supraspinal effects in the intact goat (5). Takeuchi and his colleagues demonstrated that the topical application of propofol inhibited the responses of lumbar dorsal horn wide dynamic range (WDR)-type neurons to ipsilateral noxious thermal stimulation, and suppressed the sensitization of WDR neurons induced by the allyl isothiocyanate (6).

Upon exposure to the noxious stimuli several neurotransmitters, including glutamate (Glu), γ-aminobutyric acid (GABA) and glycine (Gly), are released from the sensory afferents and nocisponsive neurons in the dorsal horn, thus integrating the peripheral nociceptive information and forwarding it to the supraspinal brain regions for pain sensation. Currently the differential effect of propofol on the neurotransmission in dorsal horn remains unclear. In this study, we applied transverse spinal microdialysis to delineate the accurate profile of propofol at different doses to affect the release of these neurotransmitters in dorsal spinal cord in the rats.
Material and Methods

Animals

Fifteen adult male Wistar rats (supplied by the medical experimental animal center in Chinese People Liberation Army General Hospital) weighing 280–350 g were used in the study. All animals were housed at a constant temperature (24 ± 0.5 °C) and relative humidity (60±2%) on a light-controlled schedule (light on between 6:00 AM and 6:00 PM), and had free access to food and water. The experimental protocols were approved by the Animal Care and Use Committee of the Chinese People Liberation Army (PLA) General Hospital (Beijing, China), and were conducted under the guidelines for the Care and Use of Laboratory Animals, formulated by the Ministry of Science and Technology of the People's Republic of China.

Propofol administration and the assessment of the anesthesia states of rats from behavioral signs

A heparinized saline-filled polyethylene catheter (OD= 0.8 mm) was inserted into the right internal jugular vein of rats under the isoflurane anesthesia for the following propofol infusion. The catheter was set under subcutaneous tissues, and the end of the catheter was secured to the nape of the neck with sutures for infusion of propofol. The rats received the propofol infusion twice with 2 days apart. The first infusion was scheduled 24 hr after catheterization to assess the effect of propofol on the anesthesia states of the rats, and the second infusion was scheduled 24 hr after the placement of the microdialysis probe to determine the effect of propofol on the neurotransmitter release in the dorsal horn.

The rats were transferred to a bowl-shape chamber 24 hr after the catheterization. Propofol (10 g/l) was continuously infused through the polyethylene catheter with a 3500 syringe pump (Graseb Medical, UK) following the schedule shown in Figure 1. The infusion rates were, in order, 400 µg/(kg-min), 600 µg/(kg-min) and 800 µg/(kg-min), and a 20 min infusion period was maintained at each infusion rate (Figure 1). Every 2 min before changing the infusion rate to the next level, vibrissal stroking test, right flex test and tail pinch test were conducted in turn to assess the anesthetic states of rats at the current time point. The rats were defined as sedate with the loss of vibrissal stroking reflex, unconsciousness with the loss of righting reflex, or immobile with the loss of tail pinch reflex. If it was assessed using vibrissal stroking test that the rat was under sedative state, the righting reflex test would then be done to evaluate the state of consciousness of the rat; if the rat was in unconscious state, the tail pinch test would then be done to evaluate if the rat was in analgesic state (immobility). Throughout the studies, the rats had spontaneous ventilation.

Microdialysis procedure

Microdialysis probes were placed as previously described (7) 24 hr after the first propofol administration. Briefly, the rat was anesthetized with chloral hydrate (350 mg/kg, intraperitoneally), and an incision along the dorsal midline from T9 to L3 was made. The T13 vertebra was cleared of muscle and two small holes were drilled into the lateral aspect on each side to expose a small portion of the spinal cord. A linear microdialysis probe (BAS MD-2005, 5 mm membrane window, 6/pkg, USA) was inserted transversely across the dorsal horn of the spinal cord through the two holes and then fixed to the bone with dental cement (S1). The polyethylene catheters at the inflow side and the outflow side of the probe were fixed at the neck via piercing the tunnel beneath the back skin. The animals were allowed to recover for 24 hr. Only the rats without significant weight loss and limb paralysis or impaired movement proceeded for further experiments.

Twenty four hours after the placement of the microdialysis probe, the rats were placed in the U-shaped chamber which is a part of a system for freely moving animals. The linear microdialysis probes were perfused with artificial cerebrospinal fluid (ACSF; 140.0 mM NaCl, 3.0 mM KCl, 1.5 mM CaCl2, 1.0 mM MgCl2, 1.5 mM Na2HPO4, 0.27 mM NaH2PO4, and pH 7.4 adjusted with 0.1 M NaOH). After a period at a rate of 5 µl/min with an infusion microvolume pump (CMA/100, CMA, Stockholm, Sweden), samples of dialysate in polyethylene vials in the refrigerated fraction collector (4°C, HoneyComb™, BAS, U.S.A) via connecting tubes (MF-5366, 0.025OD×0.005 ID, BAS, USA) were collected. Dialysates samples were collected every 20 min (100 µl) for 1 hr prior to infusion of propofol to establish the baseline level, and then propofol (10 g/l) was continuously infused. The infusion rates were, in order, 400 µg/(kg-min), 600 µg/(kg-min) and 800 µg/(kg-min), and a 20 min infusion period was maintained at each infusion rate. During the propofol anesthesia, samples were collected every 20 min (100 µl) for 1 hr. The collected samples were transferred immediately to a -80 °C freezer for amino acid detection. At the end of the experiment, all rats were killed with an overdose of pentobarbital, and the spinal cord was removed and postfixed in 10% formalin to verify the microdialysis fiber placement site.

Figure 1. Protocol of administration of propofol and collection of dialysate.
Detection of amino acids in the dialysates

The concentrations of Glu, GABA and Gly in the dialysates were measured by OPA-β-mercaptoethanol precolumn derivatization, reversed phase gradient elution and fluorescence detection. The HPLC employed buffer A: 0.1 M NaH₂PO₄ buffer (adjusted to pH 6.8); chromatographic pure methanol=70:30; and buffer B: HPLC-grade methanol. Buffer A was ultrasonically degassed, buffer B was filtered and degassed through a 0.2 mm nitrocellulose membrane. The above two-buffer HPLC system (HP1100, Agilent, U.S.A) was coupled to a fluorescent detector (1100, Agilent, USA). Separation was achieved on a C18 column (Hypersil AA-ODS, 5 µm, 2.1×200 mm, Agilent, U.S.A). The o-phthalaldehyde derivatizing reagent was prepared by dissolving 25 mg o-phthalaldehyde (Sigma, USA) in absolute methanol (0.5 ml) and adding 2-mercaptoethanol (10 µl) and borate buffer (0.4 mol/l, pH 9.4-9.5, and 5 ml). Two microliters dialysate and 10 µl OPA derivating fluid were allowed to react for 3 min at room temperature, and then the reaction mixture was injected into the column and separated with a gradient from A: B (100: 0) to 60% B within 30 min. The flow rate was set to 0.5 ml/min. Excitation wavelength was set as 340 nm, and emission wavelength was 450 nm. Detector temperature was set at 28°C.

Measurement of hemodynamic parameters

Another cohort of rats (n = 6) was used to investigate the hemodynamic changes during the propofol anesthesia. Twenty four hours before the propofol administration (same as mentioned above), the rats were anesthetized with 1.8% isoflurane, and a heparinized saline-filled polyethylene catheter was inserted into the femoral artery for the measurement of mean arterial blood pressure (MAP) and heart rate (HR) during propofol infusion.

Statistical analysis

All microdialysis data were presented as percentage ± SEM of basal values. Hemodynamic parameters were shown as mean ± SEM. Repeated measures analysis of variance was performed on amino acid levels under anesthesia with different dosages of propofol, “within” factor being time and “between” factor being different dosage of propofol treatment. Multiple comparisons were performed using LSD. Hemodynamic parameters were analyzed with one-way ANOVA. A value of P < 0.05 was considered statistically significant. All data were analyzed using the statistical software SPSS13.0.

Results

Enrolled rats

Two rats showing neurological deficits of paralysis and allostynia following the catheterization for spinal microdialysis were excluded from the experiment. The catheter in one rat was not placed in the intended spinal area. Finally, the data of twelve rats were adopted for the statistical analysis.
Table 1. Effects of increasing doses of propofol on systemic hemodynamics in rats

|               | Baseline | 400 µg/(kg·min) | 600 µg/(kg·min) | 800 µg/(kg·min) |
|---------------|----------|-----------------|-----------------|-----------------|
| HR (beats/min)| 367±47   | 374±37          | 329±39          | 323±35          |
| MAP (mmHg)    | 121±8    | 120±7           | 110±5           | 99±4            |
| PaO2 (mmHg)   | 104±9    | 102±8           | 103±9           | 98±5            |
| PaCO2 (mmHg)  | 31±1     | 30±1            | 34±2            | 35±1            |

Data are expressed as mean ± SEM. (n = 6). HR: heart rate, MAP: mean arterial blood pressure. Data analyzed by one-way ANOVA for comparison.

* P < 0.05 as compared to baseline

**Figure 3.** Effects of increasing doses of propofol on the glutamate (Glu) (A), γ-aminobutyric acid (GABA) (B) and glycine (Gly) (C) efflux in the spinal cord dorsal horns of rats. Glutamate, glycine and GABA were shown as percent compared with the data before administration of propofol. Baseline levels of glutamate, glycine and GABA were set as 100%. N = 15; Values are percentage ± SEM. * P < 0.05, ** P < 0.01 as compared to baseline; # P < 0.05, ## P < 0.01 as compared to 400 µg/(kg·min) propofol infusion; • P < 0.05 as compared to 600 µg/(kg·min) propofol infusion.

GABA efflux in the spinal dorsal horn was decreased to 84.6±9.9% at 400 µg/(kg·min) propofol infusion (P<0.001 vs baseline; n=15), 83.0±9.7% at 600 µg/(kg·min) infusion (P=0.008 vs baseline; n=15), and 82.2±15.1% at 800 µg/(kg·min) infusion (P=0.035 vs baseline; n=15) (Figure 3B). As shown in Figure 3C, The Gly efflux was decreased to 85.7±10.2% (P=0.02 vs baseline; n=15) and 80.1±12.1% (P=0.01 vs baseline; n=15) at 400 µg/(kg·min) and 600 µg/(kg·min) propofol infusion, respectively, and 83.9±10.8% at 800 µg/(kg·min) propofol infusion (P=0.015 vs baseline; n=15).

**Discussion**

Using a transverse microdialysis, we investigated the effects of increasing dosage of propofol on the Glu, GABA and Gly efflux in spinal dorsal horn. It was revealed that propofol had inhibitory action on the efflux of both excitatory and inhibitory amino acids in spinal dorsal horn, and the inhibition on the excitatory amino acids was stronger than that on the inhibitory ones. We speculated that the preferential suppression on the release of excitatory amino acids may be associated with the analgesia effect of propofol.

In the current study, propofol inhibited the efflux of Glu in spinal dorsal horn in a dose-dependent manner. Glu is contained in primary afferent fibers (PAFs) and dorsal horn neurons (8, 9), and the majority of the primary afferent synapses such as the C-fiber afferent synapses are glutamatergic synapses. The release of Glu from PAFs is inhibited (presynaptic inhibition) mainly via presynaptic opioid receptors and GABA receptors in dorsal horn (10). Activation of GABA<sub>A</sub> receptor induces the hyperpolarization of primary afferents, and produces a decrease in the amplitude of presynaptic action potentials and, consequently, the amount of transmitter released (11). GABA<sub>A</sub> and GABA<sub>B</sub> receptors have been found on the central terminals of the nociceptive fine PAFs in superficial dorsal horn, and the activation of the presynaptic GABA<sub>A</sub> and GABA<sub>B</sub> receptors reduces the release of neurotransmitters such as Glu and substance P (12, 13). Propofol is thought to exert its anesthetic action by augmenting GABA<sub>A</sub> receptor-mediated chloride current (14). Therefore, propofol might enhance GABA<sub>A</sub> receptors-mediated presynaptic inhibition at PAFs and then attenuate the release of Glu. Previous in vivo experiment reports that propofol (1 mg/kg) enhances GABA<sub>A</sub> receptor-mediated presynaptic inhibition in PAFs in human spinal cord (15). In our study, the Glu level was decreased to 80% during the low-dose propofol infusion, and the maximum decrease was about 45% at high-dose propofol infusion. The dose-response effects on the Glu release may be associated with the different actions of propofol on GABA receptors.

The present study also showed that the GABA and Gly efflux was decreased about 15–20% during the low-dose
propofol infusion, but did not continue to drop with the increased dosage of propofol.

Yamakura et al demonstrated that enhancement of GABAergic and glycinegic neurotransmission by propofol is responsible for its general anesthetic properties (16). However, this research about the molecular mechanism of general anesthesia focused on the effects of propofol on the receptors, especially the GABA<sub>A</sub> receptor which is the selective target of propofol. And the release of excitatory and the inhibitory amino acids in the spinal dorsal horn of the living rats is the global result of the action of propofol on the GABA<sub>A</sub> receptor and other potential targets. The exact mechanism for this inhibition of GABA and Gly efflux is not clear. The release of inhibitory amino acids in the spinal cord was related to the tone of a descending pain modulation pathway (17). The facilitation or inhibition of descending pain modulation pathway might influence the release of excitatory and inhibitory amino acids in the spinal cord. The decrease of GABA and Gly release may result from disinhibition of descending supraspinal inhibitory systems induced by propofol.

**Conclusion**

The current study demonstrates that propofol has inhibitory action on both excitatory and inhibitory amino acids efflux in dorsal spinal cord. Moreover, the inhibition on Glu release was stronger than that on GABA and Gly release. The imbalance of excitation and inhibition within the dorsal spinal cord might contribute to the anesthetic effects of propofol.

**Acknowledgment**

This work was supported financially by the National Natural Science Foundation of China (Grant No. 2012FC-CXYY-4044). We thank Bihua Bie for the excellent advice on manuscript writing. The results reported in this paper were part of a student thesis.

**References**

1. Collins JG, Kendig JJ, Mason P. Anesthetic actions within the spinal cord: Contributions to the state of general anesthesia. Trends Neurosci 1995; 18: 549-553.
2. Kungys G, Kim J, Jinks SL, Atherley RJ, Antognini JF. Propofol produces immobility via action in the ventral horn of the spinal cord by a GABAergic mechanism. Anesth Analg 2009; 108: 1531-1537.
3. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997; 14: 2-31.
4. Takasu T1, Yamaguchi S, Hamaguchi S, Yaksh TL. Effects of general anesthetics on substance P release and c-Fos expression in the spinal dorsal horn. Anesthesiology. 2013; 119: 443-442.
5. Antognini JF, Wang XW, Piercy M, Carstens E. Propofol directly depresses lumbar dorsal horn neuronal responses to noxious stimulation in goats. Can J Anaesth 2000; 47: 273-279.
6. Takechi K, Carstens Ml, Klein AH, Carstens E. The antinociceptive and antihyperalgesic effects of topical propofol on dorsal horn neurons in the rat. Anesth Analg 2013; 116: 932-938.
7. Skilling SR, Smullin DH, Beitz AJ, Larson AA. Extracellular amino acid concentrations in the dorsal spinal cord of freely moving rats following veratridine and nociceptive stimulation. J Neurochem 1988; 51: 127-132.
8. Shuka KA, Westlund KN. (1992). An experimental arthritis model in rats: dorsal horn aspartate and glutamate increase. Neurosci Lett 145: 141-144.
9. Valschanoff JG, Phend KD, Bernardi PS, Weinberg RJ, Rustioni A. Amino acid immunocytochemistry of primary afferent terminals in the rat dorsal horn. J Comp Neurol 1994; 346: 237-252.
10. Ataka T, Kumanoto E, Shimoji K, Yoshimura M. Baclofen inhibits more effectively C-afferent than Adelta-afferent glutamatergic transmission in substantia gelatinosa neurons of adult rat spinal cord slices. Pain 2000, 86: 273-282.
11. Engelman HS, MacDermott AB. Presynaptic ionotropic receptors and control of transmitter release. Nat Rev Neurosci 2004; 5: 135-145.
12. Ishikawa, T, Marsala, M, Sakabe, T, Yaksh TL. Characterization of spinal amino acid release and touch-evoked allodynia produced by spinal glycine or GABA (A) receptor antagonist. Neuroscience 2000; 95: 781-786.
13. Kleschevnikov AM, Belichenko PV, Gall J, George L, Nosheny MT. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 2012; 45: 683-691.
14. Manuel NA, Davies CH. Pharmacological modulation of GABA (A) receptor-mediated postsynaptic potentials in the CA1 region of the rat hippocampus. Br J Pharmacol 1998; 125: 1529-1542.
15. Shimizu M, Yamakura T, Tohiba T, Okamoto M, Ataka T, et al. Propofol enhances GABAA receptor-mediated presynaptic inhibition in human spinal cord. Neuroreport 2002; 13: 357-360.
16. Yamakura T, Bertaccini E, Trudell JR, Harris RA. Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001; 41:23–51.
17. Lu N, Han M, Yang ZL, Wang YQ, Wu GC, Zhang YQ. Nociceptin/Orphanin FQ in PAG modulates the release of amino acids, serotonin and norepinephrine in the rostral ventromedial medulla and spinal cord in rats. Pain 2010; 148: 414-425.